^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Oncomine™ Immune Response Research Assay

    Company:
    Thermo Fisher Scientific
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    2ms
    Anti-cancer Immune Activation Post Bronchoscopic Thermal Ablation in Non-small Cell Lung Cancer (ATS 2024)
    These findings suggest that bronchoscopic thermal injury of NSCLC results in an increase in antigen presentation within the TME with some features to suggest activation of a T cell-mediated immune response. The increase of CD4+ T cells and Macrophages seen within the tumour only suggests that this is a tumour-specific response. Further work is needed to elucidate these findings.
    IO biomarker
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule) • LAMP3 (Lysosomal Associated Membrane Protein 3) • CD68 (CD68 Molecule) • HLA-DRA (Major Histocompatibility Complex, Class II, DR Alpha)
    |
    Oncomine™ Immune Response Research Assay
    6ms
    Decoding the immune landscape of breast cancer (BC) during pregnancy (PrBC): Impact of hormone receptors (HR) and tumor-infiltrating lymphocytes (TILs) phenotype on gene expression signatures (SABCS 2023)
    These findings highlight the heterogeneity and distinct molecular characteristics of PrBC and EOBC. The upregulation of specific immune-related gene families, such as CT and Chemokines, in different PrBC subtypes may suggest their potential role as actionable biomarkers (e.g. MAGEA, a well-known oncogene and potential immunotherapy target).
    Tumor-infiltrating lymphocyte • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • MAGEA1 (MAGE Family Member A1) • ALOX15B (Arachidonate 15-Lipoxygenase Type B)
    |
    Oncomine™ Immune Response Research Assay
    12ms
    Immune response In Waldenström macroglobulinaemia patients after BTK inhibition (BSH 2023)
    Downregulation of CXCL13, which acts as a B lymphocyte chemoattractant, has previously been shown in both WM and chronic lymphocytic leukaemia after Ibrutinib treatment, minimising the migration of tumour cells and disrupting the TME. This pilot study has shown regions of the WM immune microenvironment with significant changes in gene expression after BTKi therapy, namely in pathways involving NK cells and type 2 interferon signalling. A larger cohort with paired samples pre and post BTKi treatment is under investigation.
    Clinical
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • NCR1 (Natural Cytotoxicity Triggering Receptor 1)
    |
    MYD88 mutation • MYD88 L265P
    |
    Oncomine™ Immune Response Research Assay
    |
    Imbruvica (ibrutinib)
    over1year
    Exploring the lymph node’s microenvironment for personalized management of luminal A breast cancer (EBCC 2022)
    A better understanding of the complex interplay between cancer cells and host immunity is essential for the choice of personalized treatment in Luminal A BC. The DEGs here identified in metastatic SLNs of Luminal A BC may improve prognosis accuracy and increase the efficacy and safety of targeted therapies. Particularly, VTCN1, CD44, NECTIN2, LRG1, CD276 and FOXM1 seems extremely promising biomarkers and potentially useful for target immunotherapy.
    IO biomarker
    |
    CD276 (CD276 Molecule) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • KRT7 (Keratin-7) • FOXM1 (Forkhead Box M1) • GATA3 (GATA binding protein 3) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
    |
    Oncomine™ Immune Response Research Assay
    over1year
    PD-L1 Expression in High-Risk Early-Stage Colorectal Cancer-Its Clinical and Biological Significance in Immune Microenvironment. (PubMed, Int J Mol Sci)
    High CXCL9 expression correlated with increased infiltration levels of immune cells in the TME, including CD8+ T lymphocytes and M1 macrophages. These findings suggest that high PD-L1 expression is a prognostic factor of early-stage CRC, and CXCL9 may play a key role in regulating PD-L1 expression.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    PD-L1 expression • PD-L1 overexpression • CXCL9 expression • CXCL9 overexpression
    |
    Oncomine™ Immune Response Research Assay
    over1year
    Longitudinal Profiling of the T Cell Compartment in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax (ASH 2022)
    Herein we interrogated the molecular and phenotypic profiles of the T cell compartment in 1 treatment-naïve and 15 relapsed/refractory CLL patients who received ven either as monotherapy (n=12) or in combination with an anti-CD20 antibody (obinutuzumab, n=1; rituximab, n=3). In conclusion, ven treatment led to increased numbers of CD8+ effector subpopulations along with prominent clonal expansions and transcriptional rewiring that could conceivably contribute to clinical response. Downregulation of immune-related genes implicated in core regulatory/activation pathways supports immune recovery by ven, offering a rationale for future combination strategies aiming to increase the depth of clinical response.
    Clinical • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD8 (cluster of differentiation 8) • CCR7 (Chemokine (C-C motif) receptor 7) • TLR9 (Toll Like Receptor 9) • ICOSLG (Inducible T Cell Costimulator Ligand) • BTLA (B And T Lymphocyte Associated) • CD40 (CD40 Molecule) • CEACAM1 (CEA Cell Adhesion Molecule 1) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • TLR7 (Toll Like Receptor 7)
    |
    BCL2 overexpression • BCL2 expression
    |
    Oncomine™ Immune Response Research Assay
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab)
    over1year
    Correlation of an immune-related 8-gene panel with the efficacy of neoadjuvant chemotherapy for breast cancer (SABCS 2022)
    We identified eight immune genes which were associated with better prognosis and drug responses. The 8-gene score may serve as a prognostic marker for breast cancer patients who receiving neoadjuvant chemotherapy.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD20 (Membrane Spanning 4-Domains A1) • CD69 (CD69 Molecule) • CD40LG (CD40 ligand) • MS4A1 (Membrane Spanning 4-Domains A1) • CD1C (CD1c Molecule) • KLRB1 (Killer Cell Lectin Like Receptor B1) • NKG2D (killer cell lectin like receptor K1)
    |
    HER-2 expression
    |
    Oncomine™ Immune Response Research Assay
    over1year
    Changes in immune gene signatures after neoadjuvant chemoimmunotherapy treatment in NSCLC patients from NADIM trial (ESMO 2022)
    Conclusions The greatest changes in the immune expression profile during neoadjuvant treatment were observed in CPR tumors reflecting an active immune response. There were little differences between paired samples of non-CPR tumors that denotes ineffective immune stimulation after treatment.
    Clinical • Gene Signature • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Oncomine™ Immune Response Research Assay
    almost2years
    Interleukin-11 dysregulates tumor immunity, promoting the tumor progression (EACR 2022)
    By DSP, we confirm that LUAD patients with high expression levels of IL-11 express lower levels of some immune markers. Conclusion Collectively, our data demonstrate that IL-11 dysregulates tumor immunity towards an immunosuppressive microenvironment favoring cancer progression.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    Oncomine™ Immune Response Research Assay
    almost2years
    Tumor Bulk-RNA Seq Identifies Patients at High Risk of Progression in Non-complete Pathological Responders from NADIM Trial (IASLC-WCLC 2022)
    The upregulated pathways in surgical samples of CPR patients suggested that an effective immune response to PD-1 blockade was done. Additionally, we have identified an immune expression signature in surgical specimens associated to disease progression for non-CPR patients which could help in the follow-up and therapeutic management of these high-risk patients.
    Clinical • PD(L)-1 Biomarker • BRCA Biomarker • IO biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TNFRSF8 (TNF Receptor Superfamily Member 8) • TOP2A (DNA topoisomerase 2-alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • KRT7 (Keratin-7) • FOXM1 (Forkhead Box M1) • MELK (Maternal Embryonic Leucine Zipper Kinase) • TWIST1 (Twist Family BHLH Transcription Factor 1) • CCNB2 (Cyclin B2) • CDK1 (Cyclin-dependent kinase 1) • CEACAM1 (CEA Cell Adhesion Molecule 1) • IFI27 (Interferon Alpha Inducible Protein 27) • KRT5 (Keratin 5) • MAGEA3 (MAGE Family Member A3) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    Oncomine™ Immune Response Research Assay
    almost2years
    DISTINCT IMMUNE-RESPONSE PROFILE OF RICHTER TRANSFORMATION: HIGH EXPRESSION OF IL-10, LAG-3 AND OTHER IMMUNE CHECKPOINT MOLECULES (EHA 2022)
    Overexpression of LAG3 in large neoplastic B-cells of RT, specifically in cases clonally-related to CLL is an important finding that may serve as a diagnostic marker. Checkpoint molecules LAG3 and TIM3 can serve as new immune-therapy targets for the treatment of RT. IL-10 blockade has been shown to enhance T-cell immunity, and may be a potential therapeutic target.
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CD79B (CD79b Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • S100A8 (S100 Calcium Binding Protein A8) • IL10 (Interleukin 10) • S100A9 (S100 Calcium Binding Protein A9) • IL18 (Interleukin 18) • TGFB1 (Transforming Growth Factor Beta 1) • TP63 (Tumor protein 63) • CD40LG (CD40 ligand) • IL1B (Interleukin 1, beta)
    |
    PD-1 overexpression • PD-1 expression • LAG3 expression • LAG3 overexpression • IL10 overexpression
    |
    Oncomine™ Immune Response Research Assay
    2years
    Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy (ELCC 2022)
    The AUC ROC for response prediction based on IFNG, GZMB expression or M1 macrophages proportion was 1.000 (p=0.0027), 0.911 (p=0.0136) and 0.9778 (p=0.004), respectively. Conclusions In our study, a pro-inflammatory profile measured in the pre-treatment tissue by RNA-sequencing is associated with CPR following neoadjuvant CI in patients with stage IIIA NSCLC.
    Clinical • PD(L)-1 Biomarker • Gene Signature • IO biomarker
    |
    IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • FASLG (Fas ligand) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • GZMB (Granzyme B) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • NCR1 (Natural Cytotoxicity Triggering Receptor 1)
    |
    IFNG expression
    |
    Oncomine™ Immune Response Research Assay
    over2years
    Tumor microenvironment characteristics and prognosis in breast cancer during pregnancy: The role of differentially expressed immune-related genes (SABCS 2021)
    PrBC TME is characterized by specific patterns of TILs subpopulations due to the possible activation of type I IFNs and its assessment might help in identifying women at high risk of death and recurrence.
    PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • FOXP3 (Forkhead Box P3) • FUT4 (Fucosyltransferase 4)
    |
    PD-L1 expression • HER-2 negative • CD8 expression • CD31 expression • IFNA1 expression • CD8 negative
    |
    PD-L1 IHC 22C3 pharmDx • Oncomine™ Immune Response Research Assay
    over2years
    Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ (SABCS 2021)
    The activation of immune-related pathways might play a part in the development of IBE in patients with a diagnosis of DCIS. The evaluation of immune-related gene expression profiles might improve risk stratification in patients with DCIS.
    Clinical • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • CCL2 (Chemokine (C-C motif) ligand 2) • CD31 (Platelet and endothelial cell adhesion molecule 1) • CD3D (CD3d Molecule) • ADORA2A (Adenosine A2a Receptor) • CD40LG (CD40 ligand) • FCGR2B (Fc Fragment Of IgG Receptor IIb)
    |
    HER-2 expression
    |
    Oncomine™ Immune Response Research Assay